nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—SMO—mammary gland—sarcoma	0.0743	0.113	CbGeAlD
Fluocinonide—SMO—myometrium—sarcoma	0.0527	0.0801	CbGeAlD
Fluocinonide—SMO—embryo—sarcoma	0.0507	0.077	CbGeAlD
Fluocinonide—SMO—seminal vesicle—sarcoma	0.0476	0.0723	CbGeAlD
Fluocinonide—SMO—connective tissue—sarcoma	0.0436	0.0662	CbGeAlD
Fluocinonide—SMO—skin of body—sarcoma	0.0393	0.0598	CbGeAlD
Fluocinonide—SMO—cardiac atrium—sarcoma	0.0344	0.0522	CbGeAlD
Fluocinonide—SMO—uterus—sarcoma	0.0342	0.0519	CbGeAlD
Fluocinonide—SMO—tendon—sarcoma	0.03	0.0455	CbGeAlD
Fluocinonide—SERPINA6—hematopoietic system—sarcoma	0.0249	0.0379	CbGeAlD
Fluocinonide—SMO—testis—sarcoma	0.0248	0.0377	CbGeAlD
Fluocinonide—SMO—liver—sarcoma	0.0234	0.0356	CbGeAlD
Fluocinonide—Leukoderma—Thiotepa—sarcoma	0.022	0.0645	CcSEcCtD
Fluocinonide—SMO—lymph node—sarcoma	0.018	0.0273	CbGeAlD
Fluocinonide—SERPINA6—bone marrow—sarcoma	0.016	0.0243	CbGeAlD
Fluocinonide—Eruption—Dactinomycin—sarcoma	0.0151	0.0442	CcSEcCtD
Fluocinonide—Folliculitis—Dactinomycin—sarcoma	0.0148	0.0433	CcSEcCtD
Fluocinonide—SERPINA6—liver—sarcoma	0.0129	0.0196	CbGeAlD
Fluocinonide—Secondary infection—Epirubicin—sarcoma	0.0128	0.0376	CcSEcCtD
Fluocinonide—NR3C1—myometrium—sarcoma	0.0127	0.0193	CbGeAlD
Fluocinonide—NR3C1—embryo—sarcoma	0.0122	0.0186	CbGeAlD
Fluocinonide—Secondary infection—Doxorubicin—sarcoma	0.0119	0.0348	CcSEcCtD
Fluocinonide—NR3C1—seminal vesicle—sarcoma	0.0115	0.0174	CbGeAlD
Fluocinonide—NR3C1—hematopoietic system—sarcoma	0.0109	0.0166	CbGeAlD
Fluocinonide—NR3C1—connective tissue—sarcoma	0.0105	0.016	CbGeAlD
Fluocinonide—NR3C1—smooth muscle tissue—sarcoma	0.00961	0.0146	CbGeAlD
Fluocinonide—NR3C1—skin of body—sarcoma	0.00949	0.0144	CbGeAlD
Fluocinonide—Dermatitis contact—Thiotepa—sarcoma	0.00926	0.0271	CcSEcCtD
Fluocinonide—Skin exfoliation—Thiotepa—sarcoma	0.00894	0.0262	CcSEcCtD
Fluocinonide—Leukoderma—Epirubicin—sarcoma	0.00887	0.026	CcSEcCtD
Fluocinonide—NR3C1—cardiac atrium—sarcoma	0.00829	0.0126	CbGeAlD
Fluocinonide—NR3C1—uterus—sarcoma	0.00825	0.0125	CbGeAlD
Fluocinonide—Leukoderma—Doxorubicin—sarcoma	0.00821	0.024	CcSEcCtD
Fluocinonide—NR3C1—lymphoid tissue—sarcoma	0.00769	0.0117	CbGeAlD
Fluocinonide—NR3C1—tendon—sarcoma	0.00722	0.011	CbGeAlD
Fluocinonide—NR3C1—bone marrow—sarcoma	0.007	0.0106	CbGeAlD
Fluocinonide—Swelling—Mitoxantrone—sarcoma	0.00666	0.0195	CcSEcCtD
Fluocinonide—Skin exfoliation—Etoposide—sarcoma	0.00643	0.0188	CcSEcCtD
Fluocinonide—Eruption—Epirubicin—sarcoma	0.00613	0.0179	CcSEcCtD
Fluocinonide—Folliculitis—Epirubicin—sarcoma	0.006	0.0176	CcSEcCtD
Fluocinonide—NR3C1—testis—sarcoma	0.00598	0.00909	CbGeAlD
Fluocinonide—Eruption—Doxorubicin—sarcoma	0.00567	0.0166	CcSEcCtD
Fluocinonide—NR3C1—liver—sarcoma	0.00566	0.00859	CbGeAlD
Fluocinonide—Folliculitis—Doxorubicin—sarcoma	0.00555	0.0162	CcSEcCtD
Fluocinonide—Swelling—Etoposide—sarcoma	0.00554	0.0162	CcSEcCtD
Fluocinonide—Hyperglycaemia—Thiotepa—sarcoma	0.0053	0.0155	CcSEcCtD
Fluocinonide—Glycosuria—Epirubicin—sarcoma	0.00466	0.0136	CcSEcCtD
Fluocinonide—Hyperglycaemia—Mitoxantrone—sarcoma	0.00458	0.0134	CcSEcCtD
Fluocinonide—NR3C1—lymph node—sarcoma	0.00434	0.00659	CbGeAlD
Fluocinonide—Glycosuria—Doxorubicin—sarcoma	0.00431	0.0126	CcSEcCtD
Fluocinonide—Immune system disorder—Thiotepa—sarcoma	0.00425	0.0124	CcSEcCtD
Fluocinonide—Erythema—Thiotepa—sarcoma	0.0041	0.012	CcSEcCtD
Fluocinonide—Erythema—Dactinomycin—sarcoma	0.00406	0.0119	CcSEcCtD
Fluocinonide—Dermatitis contact—Epirubicin—sarcoma	0.00373	0.0109	CcSEcCtD
Fluocinonide—Skin exfoliation—Epirubicin—sarcoma	0.0036	0.0105	CcSEcCtD
Fluocinonide—Erythema—Mitoxantrone—sarcoma	0.00354	0.0103	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00346	0.0101	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—sarcoma	0.00345	0.0101	CcSEcCtD
Fluocinonide—Skin exfoliation—Doxorubicin—sarcoma	0.00333	0.00975	CcSEcCtD
Fluocinonide—Infection—Thiotepa—sarcoma	0.00332	0.00972	CcSEcCtD
Fluocinonide—Infection—Dactinomycin—sarcoma	0.0033	0.00964	CcSEcCtD
Fluocinonide—Nervous system disorder—Thiotepa—sarcoma	0.00328	0.00959	CcSEcCtD
Fluocinonide—Skin disorder—Thiotepa—sarcoma	0.00325	0.0095	CcSEcCtD
Fluocinonide—Immune system disorder—Etoposide—sarcoma	0.00305	0.00893	CcSEcCtD
Fluocinonide—Infection—Vincristine—sarcoma	0.00294	0.00862	CcSEcCtD
Fluocinonide—Nervous system disorder—Vincristine—sarcoma	0.00291	0.00851	CcSEcCtD
Fluocinonide—Infection—Mitoxantrone—sarcoma	0.00287	0.00839	CcSEcCtD
Fluocinonide—Pain—Thiotepa—sarcoma	0.00286	0.00836	CcSEcCtD
Fluocinonide—Pain—Dactinomycin—sarcoma	0.00284	0.0083	CcSEcCtD
Fluocinonide—Skin disorder—Mitoxantrone—sarcoma	0.0028	0.0082	CcSEcCtD
Fluocinonide—Pain—Vincristine—sarcoma	0.00253	0.00742	CcSEcCtD
Fluocinonide—Dry skin—Epirubicin—sarcoma	0.00251	0.00734	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00249	0.00728	CcSEcCtD
Fluocinonide—Pain—Mitoxantrone—sarcoma	0.00247	0.00722	CcSEcCtD
Fluocinonide—Hypersensitivity—Thiotepa—sarcoma	0.00246	0.00721	CcSEcCtD
Fluocinonide—Nasopharyngitis—Epirubicin—sarcoma	0.00245	0.00717	CcSEcCtD
Fluocinonide—Hypersensitivity—Dactinomycin—sarcoma	0.00244	0.00715	CcSEcCtD
Fluocinonide—Infection—Etoposide—sarcoma	0.00239	0.00698	CcSEcCtD
Fluocinonide—Pruritus—Thiotepa—sarcoma	0.00236	0.00692	CcSEcCtD
Fluocinonide—Skin disorder—Etoposide—sarcoma	0.00233	0.00682	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—sarcoma	0.00232	0.0068	CcSEcCtD
Fluocinonide—Nasopharyngitis—Doxorubicin—sarcoma	0.00227	0.00663	CcSEcCtD
Fluocinonide—Dizziness—Thiotepa—sarcoma	0.00221	0.00647	CcSEcCtD
Fluocinonide—Hypersensitivity—Vincristine—sarcoma	0.00218	0.00639	CcSEcCtD
Fluocinonide—Hyperglycaemia—Epirubicin—sarcoma	0.00213	0.00625	CcSEcCtD
Fluocinonide—Hypersensitivity—Mitoxantrone—sarcoma	0.00213	0.00622	CcSEcCtD
Fluocinonide—Rash—Thiotepa—sarcoma	0.00211	0.00617	CcSEcCtD
Fluocinonide—Dermatitis—Thiotepa—sarcoma	0.00211	0.00616	CcSEcCtD
Fluocinonide—Headache—Thiotepa—sarcoma	0.00209	0.00613	CcSEcCtD
Fluocinonide—Rash—Dactinomycin—sarcoma	0.00209	0.00612	CcSEcCtD
Fluocinonide—Pain—Etoposide—sarcoma	0.00205	0.00601	CcSEcCtD
Fluocinonide—Hyperglycaemia—Doxorubicin—sarcoma	0.00198	0.00578	CcSEcCtD
Fluocinonide—Dizziness—Vincristine—sarcoma	0.00196	0.00574	CcSEcCtD
Fluocinonide—Rash—Vincristine—sarcoma	0.00187	0.00547	CcSEcCtD
Fluocinonide—Dermatitis—Vincristine—sarcoma	0.00187	0.00546	CcSEcCtD
Fluocinonide—Headache—Vincristine—sarcoma	0.00186	0.00543	CcSEcCtD
Fluocinonide—Rash—Mitoxantrone—sarcoma	0.00182	0.00533	CcSEcCtD
Fluocinonide—Dermatitis—Mitoxantrone—sarcoma	0.00182	0.00532	CcSEcCtD
Fluocinonide—Headache—Mitoxantrone—sarcoma	0.00181	0.00529	CcSEcCtD
Fluocinonide—Hypersensitivity—Etoposide—sarcoma	0.00177	0.00518	CcSEcCtD
Fluocinonide—Immune system disorder—Epirubicin—sarcoma	0.00171	0.00501	CcSEcCtD
Fluocinonide—Pruritus—Etoposide—sarcoma	0.0017	0.00497	CcSEcCtD
Fluocinonide—Erythema—Epirubicin—sarcoma	0.00165	0.00483	CcSEcCtD
Fluocinonide—Dizziness—Etoposide—sarcoma	0.00159	0.00465	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—sarcoma	0.00158	0.00463	CcSEcCtD
Fluocinonide—Erythema—Doxorubicin—sarcoma	0.00153	0.00446	CcSEcCtD
Fluocinonide—Rash—Etoposide—sarcoma	0.00151	0.00443	CcSEcCtD
Fluocinonide—Dermatitis—Etoposide—sarcoma	0.00151	0.00443	CcSEcCtD
Fluocinonide—Headache—Etoposide—sarcoma	0.0015	0.0044	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00139	0.00408	CcSEcCtD
Fluocinonide—Infection—Epirubicin—sarcoma	0.00134	0.00391	CcSEcCtD
Fluocinonide—Nervous system disorder—Epirubicin—sarcoma	0.00132	0.00386	CcSEcCtD
Fluocinonide—Skin disorder—Epirubicin—sarcoma	0.00131	0.00383	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00129	0.00377	CcSEcCtD
Fluocinonide—Infection—Doxorubicin—sarcoma	0.00124	0.00362	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—sarcoma	0.00122	0.00357	CcSEcCtD
Fluocinonide—Skin disorder—Doxorubicin—sarcoma	0.00121	0.00354	CcSEcCtD
Fluocinonide—Pain—Epirubicin—sarcoma	0.00115	0.00337	CcSEcCtD
Fluocinonide—Pain—Doxorubicin—sarcoma	0.00106	0.00312	CcSEcCtD
Fluocinonide—Hypersensitivity—Epirubicin—sarcoma	0.000992	0.0029	CcSEcCtD
Fluocinonide—Pruritus—Epirubicin—sarcoma	0.000952	0.00279	CcSEcCtD
Fluocinonide—Hypersensitivity—Doxorubicin—sarcoma	0.000918	0.00268	CcSEcCtD
Fluocinonide—Dizziness—Epirubicin—sarcoma	0.00089	0.0026	CcSEcCtD
Fluocinonide—Pruritus—Doxorubicin—sarcoma	0.000881	0.00258	CcSEcCtD
Fluocinonide—Rash—Epirubicin—sarcoma	0.000849	0.00248	CcSEcCtD
Fluocinonide—Dermatitis—Epirubicin—sarcoma	0.000848	0.00248	CcSEcCtD
Fluocinonide—Headache—Epirubicin—sarcoma	0.000843	0.00247	CcSEcCtD
Fluocinonide—Dizziness—Doxorubicin—sarcoma	0.000824	0.00241	CcSEcCtD
Fluocinonide—Rash—Doxorubicin—sarcoma	0.000785	0.0023	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—sarcoma	0.000784	0.0023	CcSEcCtD
Fluocinonide—Headache—Doxorubicin—sarcoma	0.00078	0.00228	CcSEcCtD
